This algorithm leverages the high sensitivity of HPV DNA, the built-in risk stratification of HPV 16/18 genotyping and triage with the high specificity of cytology for an optimal balance in cervical cancer screening.
Hear the physicians perspective on primary screening:
Since the FDA announced the approval of HPV testing as the primary screen for cervical cancer, there has been considerable discussion in scientific journals and in the media. Listen to Dr. Thomas C. Wright's Expert Interview surrounding the key issues at ReachMD and receive free CME credit.
The ATHENA study, the largest US prospective registrational clinical study of its kind, evaluated the performance of the HPV primary screening algorithm with the cobas ® HPV Test in women ages 25 and older.
ATHENA data indicates that screening women starting at 25 years with the cobas® HPV Test will help reduce the incidence of high-grade cervical disease